Document is current
Any future updates will be listed below
-
Authors
Middleton, Steven J. https://orcid.org/0000-0002-0708-7335
Markússon, Sigurbjörn
Åkerlund, Mikael
Deme, Justin C. https://orcid.org/0000-0001-8811-9871
Tseng, Mandy
Li, Wenqianglong
Zuberi, Sana R.
Kuteyi, Gabriel
Sarkies, Peter
Baskozos, Georgios https://orcid.org/0000-0001-9237-5878
Perez-Sanchez, Jimena https://orcid.org/0000-0002-4967-5418
Farah, Adham
Hébert, Harry L.
Toikumo, Sylvanus
Yu, Zhanru
Maxwell, Susan https://orcid.org/0009-0009-6514-149X
Dong, Yin Y.
Kessler, Benedikt M. https://orcid.org/0000-0002-8160-2446
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Linley, John E.
Smith, Blair H. https://orcid.org/0000-0002-5362-9430
Lea, Susan M. https://orcid.org/0000-0001-9287-8053
Parker, Joanne L. https://orcid.org/0000-0003-2964-2720
Lyssenko, Valeriya
Newstead, Simon https://orcid.org/0000-0001-7432-2270
Bennett, David L. https://orcid.org/0000-0002-7996-2696
- License Information
-
More Information
Article History
Received: 5 September 2024
Accepted: 24 June 2025
First Online: 20 August 2025
Competing interests
: D.L.B. has acted as a consultant for 5AM Ventures, AditumBio, AstraZeneca, Biogen, Biointervene, Combigene, GSK, Ionis, Lexicon Therapeutics, Neuvati, Novo Ventures, Olipass, Orion, Replay, SC Health Managers, Third Rock Ventures, Vida Ventures, Vertexon on behalf of Oxford University Innovation over the past two years. The PAINSTORM consortium received funding from Eli Lilly and AstraZeneca. The DOLORisk consortium received funding from Eli Lilly. J.E.L. is an employee of AstraZeneca. H.R.K. is a member of advisory boards for Altimmune and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals and Altimmune; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the past three years by Alkermes, Dicerna, Ethypharm, Imbrium, Indivior, Kinnov, Lilly, Otsuka and Pear Therapeutics; and is listed as an inventor on US provisional patent ‘Multi-ancestry Genome-wide Association Meta-analysis of Buprenorphine Treatment Response’.
